Merck, V2002-5G, Vancomycin hydrochloride from Streptomyces orientalis

Vancomycin is a nonribosomal glycopeptide antibiotic characterized by its branched, tricyclic, and glycosylated structure. Unlike beta-lactam antibiotics, vancomycin operates by inhibiting bacterial cell wall synthesis at an earlier stage. Its spectrum of activity is primarily directed against aerobic and anaerobic gram-positive bacteria, encompassing a wide range of isolates, including those that exhibit resistance to β-lactams. Vancomycin is notably effective against Gram-positive organisms such as Clostridium difficile, Listeria monocytogenes, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus viridans, Streptococcus bovis, Staphylococcus epidermidis, Actinomyces species, and Lactobacillus species. It demonstrates exceptional efficacy in combating methicillin-resistant Staphylococcus aureus (MRSA). Furthermore, vancomycin is a valuable tool for preventing the proliferation of bacterial contaminants in studies related to cell biology and biochemistry.